Eli Lilly and Company $LLY Shares Bought by Cornerstone Management Inc.

Cornerstone Management Inc. raised its holdings in Eli Lilly and Company (NYSE:LLY) by 46.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 509 shares of the company’s stock after purchasing an additional 161 shares during the period. Cornerstone Management Inc.’s holdings in Eli Lilly and Company were worth $397,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of LLY. Brighton Jones LLC grew its holdings in Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after purchasing an additional 1,730 shares during the period. Revolve Wealth Partners LLC grew its holdings in Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares during the period. Covestor Ltd grew its holdings in Eli Lilly and Company by 24.9% in the first quarter. Covestor Ltd now owns 426 shares of the company’s stock valued at $352,000 after purchasing an additional 85 shares during the period. GAMMA Investing LLC grew its holdings in Eli Lilly and Company by 25.8% in the first quarter. GAMMA Investing LLC now owns 18,000 shares of the company’s stock valued at $14,866,000 after purchasing an additional 3,696 shares during the period. Finally, Moran Wealth Management LLC grew its holdings in Eli Lilly and Company by 1.4% in the first quarter. Moran Wealth Management LLC now owns 9,453 shares of the company’s stock valued at $7,807,000 after purchasing an additional 134 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO David A. Ricks acquired 1,632 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the transaction, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. This represents a 0.30% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Gabrielle Sulzberger acquired 117 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the transaction, the director owned 2,703 shares of the company’s stock, valued at $1,733,109.54. This represents a 4.52% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 4,514 shares of company stock valued at $2,894,841 in the last 90 days. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $820.97 on Friday. Eli Lilly and Company has a one year low of $623.78 and a one year high of $935.63. The company has a market cap of $777.01 billion, a price-to-earnings ratio of 53.66, a PEG ratio of 1.16 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The business’s 50 day moving average price is $765.52 and its 200 day moving average price is $767.43.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter last year, the business posted $3.92 earnings per share. The firm’s revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on LLY shares. Leerink Partnrs lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 7th. Guggenheim reaffirmed a “buy” rating and issued a $948.00 price target on shares of Eli Lilly and Company in a research note on Thursday, October 16th. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Hsbc Global Res raised Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. Finally, DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $938.61.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.